Compounders Research Compare

ProKidney Corp.(PROK)

Biotechnology · Winston-Salem, NC

$1.58-0.01 (-0.32%)

Delayed quote: Oct 6, 2026, 3:40 PM EDT

About ProKidney Corp.

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

Winston-Salem, NC

231 employees

www.prokidney.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Bruce Culleton

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:43:00.655Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:43:00.655Z.

Quote observation: 2026-10-06T19:40:18.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 529,599,858
Total debt · period ending 2026-06-30: 3,523,000
Cash · period ending 2026-06-30: 74,868,000
TTM operating EBITDA · period ending 2026-06-30: -171,210,000

FMP input reference: 5f06b8b41e0980caada53469fccf6de542fb6b04de3a821a907ddebd40a39f21

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PROK EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

PROK Competitors' EV/EBITDA Ratio

ProKidney Corp.

Current

Market Cap

$529.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Immix Biopharma, Inc.

Market Cap

$528.79M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Delcath Systems, Inc.

Market Cap

$527.49M

EV/EBITDA Ratio

N/A

TTM Avg

144.36x

3Y Avg

144.36x

5Y Avg

144.36x

Nuvectis Pharma, Inc.

Market Cap

$525.16M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Shattuck Labs, Inc.

Market Cap

$535.91M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Phathom Pharmaceuticals, Inc.

Market Cap

$538.80M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Monopar Therapeutics Inc.

Market Cap

$539.25M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Altimmune, Inc.

Market Cap

$516.33M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aclaris Therapeutics, Inc.

Market Cap

$511.18M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BlossomHill Therapeutics, Inc.

Market Cap

$504.56M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
ProKidney Corp. (PROK)	$529.60M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$528.79M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$527.49M	N/A	144.36x	144.36x	144.36x
Nuvectis Pharma, Inc. (NVCT)vs ›	$525.16M	N/A	N/A	N/A	N/A
Shattuck Labs, Inc. (STTK)vs ›	$535.91M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$538.80M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$539.25M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$516.33M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$511.18M	N/A	N/A	N/A	N/A
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$504.56M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics